<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">nefr-235</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>МИНЕРАЛЬНО-КОСТНЫЕ НАРУШЕНИЯ У РЕЦИПИЕНТОВ ПОЧЕЧНОГО ТРАНСПЛАНТАТА</article-title><trans-title-group xml:lang="en"><trans-title>MINERAL AND BONE DISORDERS IN RENAL TRANSPLANT RECIPIENTS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ветчинникова</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Vetchinnikova</surname><given-names>O. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ветчинникова Ольга Николаевна, доктор медицинских наук, хирургическое отделение трансплантологии и диализа, кафедра трансплантологии, нефрологии и искусственных органов факультета усовершенствования врачей.</p><p>129110, Россия, Москва, ул. Щепкина, д. 61/2, корп. 6. </p><p> </p></bio><bio xml:lang="en"><p>Olga N. Vetchinnikova MD, DMedSci.</p><p>Surgical Department of Transplantology and Dialysis, Department of Transplantology, Nephrology and Artifi cial Organs Faculty of Postgraduate Medical.</p><p>129110, Russia, Moscow, Schepkina Str. 61/2, build. 6. </p></bio><email xlink:type="simple">olg-vetchinnikova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шестеро</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shestero</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шестеро Елена Владимировна, кафедра трансплантологии, нефрологии и искусственных органов факультета усовершенствования врачей, клинический ординатор. </p><p>129110, Россия, Москва, ул. Щепкина, д. 61/2, корп. 6. </p></bio><bio xml:lang="en"><p>Elena V. Shestero MD</p><p>Department of Transplantology, Nephrology and Artificial Organs Faculty of Postgraduate Medical. </p><p>129110, Russia, Moscow, Schepkina Str. 61/2, build. 6. </p></bio><email xlink:type="simple">alenca0606@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Егорова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Еgorova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Егорова Екатерина Александровна, лабораторный отдел, врач лабораторной диагностики. </p><p> 129110, Россия, Москва, ул. Щепкина, д. 61/2, корп. 6. </p></bio><bio xml:lang="en"><p>Ekaterina A. Еgorova, MD </p><p>Laboratory Department. </p><p>129110, Russia, Moscow, Schepkina Str. 61/2, build. 6. </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow regional research and clinical institute named after M.F. Vladimirsky</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>03</day><month>03</month><year>2017</year></pub-date><volume>20</volume><issue>6</issue><fpage>49</fpage><lpage>56</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ветчинникова О.Н., Шестеро Е.В., Егорова Е.А., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Ветчинникова О.Н., Шестеро Е.В., Егорова Е.А.</copyright-holder><copyright-holder xml:lang="en">Vetchinnikova O.N., Shestero E.V., Еgorova E.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/235">https://journal.nephrolog.ru/jour/article/view/235</self-uri><abstract><p>ЦЕЛЬ – оценить распространенность и тяжесть минерально-костного обмена у пациентов с хронической болезнью почек (ХБП), перенесших трансплантацию почки. ПАЦИЕНТЫ И МЕТОДЫ. В исследование включены 77 больных (32 мужчины, 45 женщин, медиана возраста 44 года) с ХБП, перенесших трансплантацию трупной почки с 2011 по 2015 г. Сывороточные концентрации электролитов, активности общей щелочной фосфатазы (ЩФ), альбумина, параметров азотистого метаболизма определяли по стандартным методикам, паратиреоидный гормон (ПТГ) и витамин D (25-ОН витамин D) в плазме крови – хемилюминесцентным иммуноанализом на системе ARСHITECT. Проведен перерасчет сывороточной концентрации кальция на сывороточную концентрацию альбумина, скорость клубочковой фильтрации (CКФ) рассчитана по формуле CKD-EPI. РЕЗУЛЬТАТЫ. Гиперкальциемия, гипофосфатемия, гипомагниемия и высокий уровень ПТГ диагностированы у 15,6, 16,9, 16,9 и 87% соответственно. Определялась высокодостоверная разница между содержанием ПТГ в крови у пациентов с нормальной и сниженной функцией почечного трансплантата. Уровень витамина D в крови колебался от 6 до 30 нг/мл (медиана 14), только один пациент имел рекомендуемый диапазон (≥30 нг/мл).Установлена обратная корреляционная зависимость ПТГ с СКФ (r=–0,543, р&lt;0,001) и с сывороточной концентрацией магния (r=–0,241, р=0,04), прямая с активностью общей ЩФ (r=0,280, р=0,015). Не установлено ассоциативной связи между содержанием в крови ПТГ и сывороточными концентрациями фосфора и кальция. Определялась слабая корреляционная связь между сывороточной концентрацией фосфора и СКФ (r=–0,232, р=0,04), между активностью ЩФ и СКФ (r=0,267, р=0,02) и между сывороточной концентрацией магния и СКФ (r=0,230, р=0,05). ЗАКЛЮЧЕНИЕ. К распространенным проявлениям минерально-костных нарушений у реципиентов почечного трансплантата относятся пре и посттрансплантационный гиперпаратиреоз, развитие/прогрессирование которого ассоциируется с гипомагниемией, ухудшением функции почки, а также дефицит витамина D.</p></abstract><trans-abstract xml:lang="en"><p>THE AIM of the study was to determine the prevalence and severity of mineral and bone metabolism in patients with chronic kidney disease (CKD) undergoing renal transplant. PATIENTS AND METHODS. The study included 77 patients (32 men, 45 women, mean age 44) with CKD who underwent transplantation of cadaveric kidneys from 2011 to 2015. Serum concentrations of electrolytes, the activity of total alkaline phosphatase (ALP), albumin, nitrogen metabolism parameters were determined by standard methods, blood concentrations of parathyroid hormone (PTH) and vitamin D (25-OH vitamin D) – by chemilumescent analysis on ARCHITECT-system. Serum calcium on serum albumin is reassessed, glomerular filtration rate (GFR) is calculated according to the formula CKD-EPI. RESULTS. Hypercalcemia, hypophosphatemia, hypomagnesemia and a high level of PTH respectively diagnosed in 15.6%, 16.9%, 16.9% and 87% patients. There was the high significant difference between blood PTH in patients with normal renal function and reduced renal graft function. The blood level of vitamin D ranged from 6 to 30 ng/ mL (median 14), only one patient was in a recommended range (≥30 ng/ml). There was the invert correlation of PTH with GFR (r=-0.543, p&lt;0.001) and serum magnesium (r=-0.241, p=0.04), directl correlation with total ALP activity (r=0.280, p=0.015). The blood PTH is not associated with serum calcium and phosphorus. There was weak invert correlation between serum phosphorus and GFR (r=-0.232, p=0.04), between ALP activity and GFR (r =-0.267, p=0.02) and between serum magnesium and GFR (r=-0.230, p=0.05). CONCLUSION. Common manifestations of mineral and bone disorders in renal transplant recipients are pre- and post-transplantation hyperparathyroidism, which development/progression is associated with hypomagnesemia, deterioration of kidney function, as well as deficiency of vitamin D.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>трансплантация почки</kwd><kwd>минеральный обмен</kwd><kwd>посттрансплантационный гиперпаратиреоз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>kidney transplantation</kwd><kwd>mineral metabolism</kwd><kwd>post-transplantation hyperparathyroidism</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kinnaert P, Nagy N, Decoster-Gervy C et al. Persistent Hyperparathyroidism Requiring Surgical Treatment after Kidney Transplantation. World J Surg 2000; 24: 1391–1395</mixed-citation><mixed-citation xml:lang="en">Kinnaert P, Nagy N, Decoster-Gervy C et al. Persistent Hyperparathyroidism Requiring Surgical Treatment after Kidney Transplantation. World J Surg 2000; 24: 1391–1395</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Evenepoel P, Claes K, Kuypers D et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: A single-centre study. Nephrol Dial Transplant 2004; 19: 1281–1287</mixed-citation><mixed-citation xml:lang="en">Evenepoel P, Claes K, Kuypers D et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: A single-centre study. Nephrol Dial Transplant 2004; 19: 1281–1287</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kawarazaki H, Shibagaki Y, Fukumoto S et al. Natural History of Mineral and Bone Disorders After Living-Donor Kidney Transplantation: A One-Year Prospective Observational Study. TherApher Dial 2011; 15(5): 481–487</mixed-citation><mixed-citation xml:lang="en">Kawarazaki H, Shibagaki Y, Fukumoto S et al. Natural History of Mineral and Bone Disorders After Living-Donor Kidney Transplantation: A One-Year Prospective Observational Study. TherApher Dial 2011; 15(5): 481–487</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bhan I, Shah A, Holmes J еt al. Post-transplant hypophosphatemia: Tertiary Hyper-Phosphatoninism? Kidney Int 2006; 70: 1486–1494</mixed-citation><mixed-citation xml:lang="en">Bhan I, Shah A, Holmes J еt al. Post-transplant hypophosphatemia: Tertiary Hyper-Phosphatoninism? Kidney Int 2006; 70: 1486–1494</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Evenepoel P, Naesens M, Claes K et al. Tertiary hyperphosphatoninism accentuates hypophosphatemia and suppresses calcitriol level in renal transplant recipients. Am J Transplant 2007; 7: 1193–1200</mixed-citation><mixed-citation xml:lang="en">Evenepoel P, Naesens M, Claes K et al. Tertiary hyperphosphatoninism accentuates hypophosphatemia and suppresses calcitriol level in renal transplant recipients. Am J Transplant 2007; 7: 1193–1200</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Evenepoel P, Meijers BK, de Jonge H et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 2008; 3: 1829–1836</mixed-citation><mixed-citation xml:lang="en">Evenepoel P, Meijers BK, de Jonge H et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 2008; 3: 1829–1836</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Есаян АМ, Каюков ИГ, Нимгирова АН и др. Фактор роста фибробластов 23-го типа у реципиентов почечного аллотрансплантата. Нефрология 2012; 16 (4): 50–54. [Esayan AM, Kayukov IG, Nimgirova AN i dr. Factor rosta fibroblastov 23 tipa u recipientov pochechnogo allotransplantata. Nefrologija 2012; 16 (4): 50–54]</mixed-citation><mixed-citation xml:lang="en">Есаян АМ, Каюков ИГ, Нимгирова АН и др. Фактор роста фибробластов 23-го типа у реципиентов почечного аллотрансплантата. Нефрология 2012; 16 (4): 50–54. [Esayan AM, Kayukov IG, Nimgirova AN i dr. Factor rosta fibroblastov 23 tipa u recipientov pochechnogo allotransplantata. Nefrologija 2012; 16 (4): 50–54]</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Evenepoel P, Lerut E, Naesens M. Localization, etiology and impact of calcium phosphate deposits in renal allografts. A J Transplant 2009; 9: 2470–2478</mixed-citation><mixed-citation xml:lang="en">Evenepoel P, Lerut E, Naesens M. Localization, etiology and impact of calcium phosphate deposits in renal allografts. A J Transplant 2009; 9: 2470–2478</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bleskestad IH, Bergrem H, Leivestad T et al. Intact parathyroid hormone levels in renal transplant patients with normal transplant function. Clin Transplant 2011; 25: E566–E570</mixed-citation><mixed-citation xml:lang="en">Bleskestad IH, Bergrem H, Leivestad T et al. Intact parathyroid hormone levels in renal transplant patients with normal transplant function. Clin Transplant 2011; 25: E566–E570</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Dumoulin G, Hory B, Nguyen NU et al. No trend towards a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients. Am J Kidney Dis 1997; 29: 746–753</mixed-citation><mixed-citation xml:lang="en">Dumoulin G, Hory B, Nguyen NU et al. No trend towards a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients. Am J Kidney Dis 1997; 29: 746–753</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Torres A, Rodriguez AP, Concepcion MT et al. Parathyroid function in long-term renal transplant patients: importance of pretransplant PTH concentrations. Nephrol Dial Transplant 1998; 13 [Suppl 3]: 94–97</mixed-citation><mixed-citation xml:lang="en">Torres A, Rodriguez AP, Concepcion MT et al. Parathyroid function in long-term renal transplant patients: importance of pretransplant PTH concentrations. Nephrol Dial Transplant 1998; 13 [Suppl 3]: 94–97</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">National kidney foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003; 42 (Suppl. 3): S1–S202</mixed-citation><mixed-citation xml:lang="en">National kidney foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003; 42 (Suppl. 3): S1–S202</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Supp 2013; 3(1): 1–150</mixed-citation><mixed-citation xml:lang="en">Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Supp 2013; 3(1): 1–150</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Нефрология. Клинические рекомендации. Ред.: Шилов ЕМ, Смирнов АВ, Козловская НЛ. ГЭОТАР-Медиа, М., 2016, 816 с. [Nefrologija. Klinicheskie rekomendacii. Red.: Shilov EM, Smirnov AV, Kozlovskaja NL. GEOTAR-Media, M., 2016, 816 s.]</mixed-citation><mixed-citation xml:lang="en">Нефрология. Клинические рекомендации. Ред.: Шилов ЕМ, Смирнов АВ, Козловская НЛ. ГЭОТАР-Медиа, М., 2016, 816 с. [Nefrologija. Klinicheskie rekomendacii. Red.: Shilov EM, Smirnov AV, Kozlovskaja NL. GEOTAR-Media, M., 2016, 816 s.]</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Добронравов ВА. Современный взгляд на патофизиологию вторичного гиперпаратиреоза: роль фактора роста фибробластов 23 и Klotho. Нефрология 2011; 15 (4): 11–20 [Dobronravov VA. Sovremenniy vzgliad na patofiziologiyu vtorichnogo giperparatireoza: rol` factora rosta fibroblastov 23 i Klotho. Nefrologija 2011; 15 (4): 11–20]</mixed-citation><mixed-citation xml:lang="en">Добронравов ВА. Современный взгляд на патофизиологию вторичного гиперпаратиреоза: роль фактора роста фибробластов 23 и Klotho. Нефрология 2011; 15 (4): 11–20 [Dobronravov VA. Sovremenniy vzgliad na patofiziologiyu vtorichnogo giperparatireoza: rol` factora rosta fibroblastov 23 i Klotho. Nefrologija 2011; 15 (4): 11–20]</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Гребенникова ТА, Белая ЖЕ, Цориев ТТ и др. Эндокринная функция костной ткани. Остеопороз и остеопатии 2015; 1: 28–37 [Grebennikova TA, Belaya ZhE, Tsoriev TT i dr. Endocrinnaia funkciya kostnoy tkani. Osteoporoz i osteopatii 2015; 1: 28–37]</mixed-citation><mixed-citation xml:lang="en">Гребенникова ТА, Белая ЖЕ, Цориев ТТ и др. Эндокринная функция костной ткани. Остеопороз и остеопатии 2015; 1: 28–37 [Grebennikova TA, Belaya ZhE, Tsoriev TT i dr. Endocrinnaia funkciya kostnoy tkani. Osteoporoz i osteopatii 2015; 1: 28–37]</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Fukumoto S, Martin TJ. Bone as an endocrine organ. Trends Endocrinol Metab 2009; 20 (5): 230 – 236. doi: 10.1016/j.tem.2009.02.001</mixed-citation><mixed-citation xml:lang="en">Fukumoto S, Martin TJ. Bone as an endocrine organ. Trends Endocrinol Metab 2009; 20 (5): 230 – 236. doi: 10.1016/j.tem.2009.02.001</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Endocrine Society. Evolution, treatment and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911–1930; PMID: 21646368; http://dx.doi.org/10.1210/ jc.2011-0385</mixed-citation><mixed-citation xml:lang="en">Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Endocrine Society. Evolution, treatment and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911–1930; PMID: 21646368; http://dx.doi.org/10.1210/ jc.2011-0385</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SM, Choi HJ, Lee JP et al. Prevalence of vitamin D deficiency and effects of supplementation with cholecalciferol in patients with chronic kidney disease. J Renal Nutr 2014; 24 (1): 20–25; http://dx.doi.org/10.1053/ j.jrn.2013.07.003</mixed-citation><mixed-citation xml:lang="en">Kim SM, Choi HJ, Lee JP et al. Prevalence of vitamin D deficiency and effects of supplementation with cholecalciferol in patients with chronic kidney disease. J Renal Nutr 2014; 24 (1): 20–25; http://dx.doi.org/10.1053/ j.jrn.2013.07.003</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Никольская ИГ, Ветчинникова ОН. Влияние беременности и хронической болезни почек на минерально-костный метаболизм. VIII съезд Научного общества нефрологов России. Сборник тезисов. Москва, 11-13 ноября 2015 г. С. 76 [Nikol`skaya IG, Vetchinnikova ON. Vliyanie beremennosti i chronicheskoy bolezni pochek na mineral`niy i kostniy metabolism. VIII s`ezd Nauchnogo obcshestva nefrologov Rossii. Sbornik tezisov. Moskva. S.76]</mixed-citation><mixed-citation xml:lang="en">Никольская ИГ, Ветчинникова ОН. Влияние беременности и хронической болезни почек на минерально-костный метаболизм. VIII съезд Научного общества нефрологов России. Сборник тезисов. Москва, 11-13 ноября 2015 г. С. 76 [Nikol`skaya IG, Vetchinnikova ON. Vliyanie beremennosti i chronicheskoy bolezni pochek na mineral`niy i kostniy metabolism. VIII s`ezd Nauchnogo obcshestva nefrologov Rossii. Sbornik tezisov. Moskva. S.76]</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Wacker M, Holick MF. Vitamin D – effects on skeletal and extraskeletal health and theneed for supplementation. Nutrients 2013; 5: 111–148; PMID: 23306192; http:// dx.doi.org/10.3390/nu5010111</mixed-citation><mixed-citation xml:lang="en">Wacker M, Holick MF. Vitamin D – effects on skeletal and extraskeletal health and theneed for supplementation. Nutrients 2013; 5: 111–148; PMID: 23306192; http:// dx.doi.org/10.3390/nu5010111</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Schottker B, Haug U, Schomburg L et al. Strong association of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer and respiratory disease mortality in a large cohort study. Am J Clin Nutr 2013; 97: 782–793; PMID: 23446902; http://dx.doi.org/10.3945/ ajcn. 112.047712</mixed-citation><mixed-citation xml:lang="en">Schottker B, Haug U, Schomburg L et al. Strong association of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer and respiratory disease mortality in a large cohort study. Am J Clin Nutr 2013; 97: 782–793; PMID: 23446902; http://dx.doi.org/10.3945/ ajcn. 112.047712</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
